Luyckx, Valerie A. http://orcid.org/0000-0001-7066-8135
Rule, Andrew D. http://orcid.org/0000-0003-0338-7784
Tuttle, Katherine R. http://orcid.org/0000-0002-2235-0103
Delanaye, Pierre http://orcid.org/0000-0002-1480-5761
Liapis, Helen
Gandjour, Afschin http://orcid.org/0000-0002-4262-8344
Romagnani, Paola http://orcid.org/0000-0002-1774-8088
Anders, Hans-Joachim http://orcid.org/0000-0003-2434-2956
Article History
Accepted: 2 November 2021
First Online: 8 December 2021
Competing interests
: P.D. has received consultancy fees from Bayer and AstraZeneca. K.R.T. has received consulting fees for diabetes and CKD from Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca, Gilead, Goldfinch Bio, Novo Nordisk and Bayer. A.G. has received consulting and lecture fees from Fresenius Medical Care. H.-J.A. has received consultancy fees from Bayer, Janssen, GSK, Novartis, Boehringer, AstraZeneca and PreviPharma. The other authors declare no competing interests.